These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8456712)

  • 1. MR appearance of extravasated gadolinium contrast medium.
    Carrier DA; Ford JJ; Hayman LA
    AJNR Am J Neuroradiol; 1993; 14(2):363-4. PubMed ID: 8456712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance].
    Campos A; Aznar L; Alamar R; Castelló JV
    Med Clin (Barc); 1996 Feb; 106(5):197. PubMed ID: 8684023
    [No Abstract]   [Full Text] [Related]  

  • 3. Anaphylactoid reactions to i.v. gadopentetate dimeglumine.
    Tishler S; Hoffman JC
    AJNR Am J Neuroradiol; 1990; 11(6):1167; discussion 1168-9. PubMed ID: 2124049
    [No Abstract]   [Full Text] [Related]  

  • 4. Measurement of relative cerebral blood volume changes with visual stimulation by 'double-dose' gadopentetate-dimeglumine-enhanced dynamic magnetic resonance imaging.
    Frank JA; Mattay VS; Duyn J; Sobering G; Barrios FA; Zigun J; Sexton R; Kwok P; Woo J; Moonen C
    Invest Radiol; 1994 Jun; 29 Suppl 2():S157-60. PubMed ID: 7928216
    [No Abstract]   [Full Text] [Related]  

  • 5. Pruritus and paresthesia after i.v. administration of Gd-DTPA.
    Chan K; Bosanko CM; Wang AM
    AJNR Am J Neuroradiol; 1989; 10(5 Suppl):S53. PubMed ID: 2505565
    [No Abstract]   [Full Text] [Related]  

  • 6. Generalized seizure after i.v. administration of gadopentetate dimeglumine.
    Harbury OL
    AJNR Am J Neuroradiol; 1991; 12(4):666. PubMed ID: 1882740
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial.
    Niendorf HP; Haustein J; Louton T; Beck W; Laniado M
    Invest Radiol; 1991 Nov; 26 Suppl 1():S221-3; discussion S232-5. PubMed ID: 1808134
    [No Abstract]   [Full Text] [Related]  

  • 8. Potential neurotoxic effects of gadopentetate dimeglumine: clinical significance.
    Alhassan A; Weinmann HJ
    AJNR Am J Neuroradiol; 1997 Apr; 18(4):785-6; author reply 786-8. PubMed ID: 9127052
    [No Abstract]   [Full Text] [Related]  

  • 9. Contrast enhancement of the gastrointestinal tract on MR images using intravenous gadolinium-DTPA.
    Mirowitz SA
    Abdom Imaging; 1993; 18(3):215-9. PubMed ID: 8508075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral contrast media for the magnetic resonance tomography of the abdomen. A clinical trial of the tolerance for gadolinium-DTPA].
    Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Felix R
    Rofo; 1992 Jan; 156(1):17-23. PubMed ID: 1733470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine.
    Witte RJ; Anzai LL
    AJNR Am J Neuroradiol; 1994 Mar; 15(3):523-4. PubMed ID: 8197951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Artificial contrasting during magnetic resonance tomography].
    Sergeev PV; Panov OV; Egorova SV; Bolotova EN; Shimanovskii NL; Akhadov TA; Sviridov NK
    Vestn Rentgenol Radiol; 1997; (1):45-52. PubMed ID: 9133071
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical safety of gadopentetate dimeglumine.
    Nelson KL; Gifford LM; Lauber-Huber C; Gross CA; Lasser TA
    Radiology; 1995 Aug; 196(2):439-43. PubMed ID: 7617858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MR imaging of pituitary region lesions with gadodiamide injection.
    Hald JK; Skalpe IO; Bakke SJ; Nakstad PH
    Acta Radiol; 1994 Jan; 35(1):65-9. PubMed ID: 8305277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The question of dose for gadolinium chelates in magnetic resonance imaging.
    Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
    Invest Radiol; 1994 Jun; 29 Suppl 2():S154-6. PubMed ID: 7928215
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute Encephalopathy and Cardiac Arrest Induced by Intrathecal Gadolinium Administration.
    Besteher B; Chung HY; Mayer TE; Witte OW; Kirchhof K; Schwab M
    Clin Neuroradiol; 2020 Sep; 30(3):629-631. PubMed ID: 31679044
    [No Abstract]   [Full Text] [Related]  

  • 17. Hemodynamic effects of bolus injection of gadodiamide injection and gadopentetate dimeglumine as contrast media at MR imaging in rats.
    Mühler A; Saeed M; Brasch RC; Higgins CB
    Radiology; 1992 May; 183(2):523-8. PubMed ID: 1561362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging detection of extraluminal enterally administered gadopentetate dimeglumine in a rat model of intestinal ischemia.
    Montalbano JM; Lee FT; Grist TM; Rappe AH; Weiss JW; Kelcz F; Gribenko V
    Acad Radiol; 1996 Jun; 3(6):486-92. PubMed ID: 8796706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadopentetate dimeglumine as a bowel contrast agent: safety and efficacy.
    Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Langer M; Claussen C; Felix R
    Radiology; 1991 Feb; 178(2):503-8. PubMed ID: 1987615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gadolinium-DTPA dimeglumine administered orally for the study of the abdomen with magnetic resonance. Clinical evaluation and tolerance].
    Squillaci E; Crecco M; Cecconi L; Lupoi D; Sergiacomi GL; Simonetti G
    Radiol Med; 1993 Sep; 86(3):284-93. PubMed ID: 8210538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.